CompletedPhase 3NCT01152554

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Studying Mal de débarquement

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Principal Investigator: Hans A. Eriksson, MD, Ph.D, MBA
AstraZeneca
Intervention: TC-5214(drug)
Enrollment: 813 target
Eligibility: 18-65 years · All sexes
Timeline: 2010 – 2012

Study locations (30)

Research Site, Birmingham, Alabama, United States
Research Site, Tuscaloosa, Alabama, United States
Research Site, Tucson, Arizona, United States
Research Site, Little Rock, Arkansas, United States
Research Site, Arcadia, California, United States
Research Site, Beverly Hills, California, United States
Research Site, Carson, California, United States
Research Site, Cerritos, California, United States
Research Site, Chino, California, United States
Research Site, Costa Mesa, California, United States
Research Site, Encino, California, United States
Research Site, Escondido, California, United States
Research Site, Garden Grove, California, United States
Research Site, Irvine, California, United States
Research Site, Los Alamitos, California, United States
+15 more locations on ClinicalTrials.gov

Collaborators

Targacept Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01152554 on ClinicalTrials.gov

Other trials for Mal de débarquement

Additional recruiting or active studies for the same condition.

See all trials for Mal de débarquement →

← Back to all trials